Close Menu

NEW YORK — Epigenomics on Thursday reported a 30 percent year-over-year increase in revenues for the third quarter of 2020, but the firm continues to face uncertainty following a recent negative reimbursement decision in the US for its flagship colon cancer screening test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.